Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

NCT00369707 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Rituximab
DRUG: bortezomib

Sponsor

Northwestern University

Collaborators

[object Object]